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
ABSTRACT 
 
The clinical utility of a life quality score during vincristine chemotherapy of dogs with canine transmissible 
venereal tumor (CTVT) was investigated using 93 tumor-bearing dogs in this prospective study. At diagnosis, 
clinical data and the performance status were evaluated according to a modified Karnofsky score (CKS) 
adapted for dogs. The animals were treated with vincristine sulphate (0.025mg/kg) at weekly intervals until the 
tumor had macroscopically disappeared. The time until the first adverse event and death were recorded. In a 
pilot study, CKS revealed a high inter-observer concordance (kappa=0.735; weighted kappa=0.835). CKS 
permitted a detailed monitoring of adverse effects during therapy. Cox regressions showed that low 
performance score and reduced body weight were independent predictive factors for death during 
chemotherapy. The modified Karnofsky performance score is a simple and reproducible clinical instrument, 
able to estimate patient outcome after treatment of CTVT. 
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RESUMO 
 
Investigou-se a utilidade clínica de uma escala de qualidade de vida durante o tratamento quimioterápico de 
cães com tumor venéreo transmissível canino (TVTC) em 93 animais com TVTC que compuseram este estudo 
prospectivo. Ao diagnóstico, foram avaliados os dados clínicos e o escore de qualidade de vida adaptado para 
cães (CKS). Os animais foram tratados com sulfato de vincristina (0.025mg/kg) semanalmente até o 
desaparecimento macroscópico do tumor. Foram anotados o tempo até o aparecimento do primeiro evento 
adverso e a morte. Em estudo piloto do CKS, alta concordância entre os observadores foi demonstrada (kappa 
= 0.735; weighted kappa = 0.835). O CKS permitiu um detalhado monitoramento dos eventos adversos 
durante a terapia. A regressão Cox multivariada demonstrou que o baixo escore de qualidade de vida e o 
reduzido peso corporal foram fatores preditivos independentes para o óbito durante a quimioterapia. A escala 
modificada de Karnofsky é um instrumento clínico simples e reproduzível, hábil em estimar os efeitos do 
tratamento no TVTC. 
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INTRODUCTION 
 
The canine transmissible venereal tumor 
(CTVT), which affects predominantly external 
genitalia, is easily transmitted through injured 
skin and mucosa by transplantation during sexual 
intercourse. There is strong evidence that the 
tumor was originated from a wolf or an East 
Asian breed of dog between 200 and 2,500 years 
ago and from than on had been transmitted from 
animal to animal like a parasite (Murgia et al., 
2006). The tumor is commonly diagnosed in free 
roaming dogs and is frequently found in rural 
areas of the State of São Paulo, which has a high 
density of the canine population estimated in 
about one dog per four inhabitants (Alves et al., 
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2005). Tumor-bearing dogs are often brought  
by the local inhabitants to the Centers of 
Zoonosis Control. Although there are several 
types of treatment, such as surgical  
excision, radiotherapy, or immunotherapy, 
monochemotherapy with vincristine is 
considered to be very effective and less toxic 
than other therapeutic interventions (Nak et al., 
2005).  
 
Nevertheless, during treatment of CTVT, 
vincristine may cause different side-effects, such 
as gastrointestinal symptoms (nausea, vomiting, 
and diarrhea), weight loss and anorexia, 
depression and paralysis, elevated body 
temperature, myelosuppression, hair loss, or 
neurological symptoms, as well as quantitative 
and qualitative alterations of semen. Even death 
has been reported (Nak et al., 2005). Regarding 
the high number of CTVTs to be treated and the 
household budget restrictions in governmental 
institutions, it is necessary to look for simple and 
cheap diagnostic procedures which would enable 
us to accompany treatment or even predict 
treatment outcome of CTVT. 
 
Performance status or quality of life scores are 
important in human medicine (Lorand-Metze et 
al., 2004), but also of increasing interest in 
veterinary sciences (Hahn et al., 1994; Yazbek 
and Fantoni, 2005). Performance scores are 
applied for pre-treatment evaluations of 
oncologic patients, since they have shown to be 
predictive for therapy outcome. 
 
The aim of this prospective study was to 
investigate whether clinical characteristics at 
diagnosis and particularly a performance score 
could indicate an increased risk for adverse 
events or death during vincristine therapy.  
 
MATERIAL AND METHODS 
 
Ninety-three dogs with naturally occurring 
CTVT were prospectively evaluated from 2003 
to 2007 at the Center of Zoonosis Control, 
Taubaté, in the State of São Paulo. The study 
was approved by the Committee of Ethics in 
Animal Research at the Universidade Estadual de 
Campinas (UNICAMP). 
 
A punch biopsy of the tumor was performed 
under atropine sulfate (0.1mg/kg) and anesthesia 
with xylazine (3mg/kg) and ketamine 
hydrochloride (15mg/kg). HE-stained cytological 
touch preparations were done. In every case, the 
diagnosis of CTVT was confirmed by 
microscopic examination of the cytologic slides, 
according to the morphologic criteria previously 
published (Santos et al., 2001; Santos et al., 
2008). All animals were subjected to clinical 
examinations. Concomitant diseases, breed, 
gender, weight, age, status as owned dog, tumor 
volume (estimated with calipers according to the 
formula: length×width×height×/6), and the 
season of the year were recorded. The months 
from June to August, were defined as „cold and 
dry period‟ (mean minimal monthly temperature 
[±SD]: 9.9±3.8°C; mean maximal monthly 
temperature: 25.0±4.5°C; 3.3±2.03 average days 
of precipitation per month), as opposed to the 
remaining of the year, which was termed „hot 
and rainy‟ (mean minimal monthly temperature: 
15.5±3.1°C; mean maximal monthly 
temperature: 27.4±2.8°C; 12.3±4.7 average days 
of precipitation per month).  
 
The performance status was evaluated at 
diagnosis and at weekly intervals during 
treatment by a modified Karnofsky Performance 
Score (Karnofsky and Burchenal, 1949), adapted 
for dogs (canine Karnofsky score, CKS) (Table 
1). The modified Karnofsky score tries to 
evaluate to what extent the tumor, concomitant 
diseases, or treatment side effects compromise 
quality of life and restrict normal activities or 
even essential for daily life, such as food and 
water intake. The term „localized accompanying 
disease of minor importance‟ is equivalent to 
minor pathologic alterations restricted to one 
organ, which do not provoke systemic 
alterations, such as fever or lethargy and which 
do not compromise activities of daily life (e.g.: 
purulent vaginal secretion, neoplasm with 
ulcerated surface, cough without fever, etc). 
„Localized accompanying disease of major 
importance‟ reflects a more severe pathologic 
alteration of an organ, always accompanied by 
generalized systemic alterations such as fever or 
lethargy (e.g.: pneumonia). For comparison, the 
simplified Karnofsky score (SKS) was 
determined (Hahn and Richardson, 1995), which 
is defined as following: 0: uncompromised 
quality of life, 1: demonstrating clinical signs 
directly related to the disease without 
compromised quality of life, 2: compromised 
quality of life with normal defecation and 
urination behavior, 3: severely compromised 
quality of life, and 4: dead.  
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Table 1. Human Karnofsky Performance Score and Karnofsky score adapted for dogs 
Score 
Karnofsky score in 
human medicine 
Karnofsky score adapted for dogs (CKS) 
100 Normal, no complaints, no evidence 
of disease. 
Normal activities of daily living (ADL), no clinical 
evident alterations even with the presence of a small 
asymptomatic tumor. 
90 Able to carry on normal activity: 
minor symptoms of disease. 
Normal ADL, one organ with localized accompanaying 
disease of minor importance. 
80 Normal activity with effort: some 
symptoms of disease. 
Normal ADL, two organs with localized accompanying 
disease of minor importance. 
70 Cares for self: unable to carry on 
normal activity or active work. 
At least one organ with accompanying disease of major 
importance. Mild letargy over baseline (letargy grade 
1); normal appetite. 
60 Requires occasional assistance but is 
able to care for needs. 
At least one organ with accompanying disease of major 
importance. Moderate lethargy causing some dificulty 
with performing ADL (letargy grade 2). Slightly 
decreased appetite and normal water intake. 
50 Requires considerable assistance and 
frequent medical care. 
At least one organ with accompanying disease of major 
importance. Letargy grade 2. Moderately decreased 
appetite,  normal water intake. 
40 Disable: requires special care and 
assistance. 
Severely restricited in ADL. Ambulatory only to the 
point of performing ADL (letargy grade 3). Severly 
decreased appetite. Spontaneous water intake slightly 
reduced, but without clinical signs of dehydration. 
30 Severely disabled: hospitalization, 
death not imminent. 
Letargy grade 3. Animal still stands up spontaneously 
and remains standing for a while; restrainment 
necessary during examinations or therapy. Severly 
decreased appetite and spontaneous water intake, 
clinical signs of dehydration. 
20 Very sick, hospitalization necessary: 
active treatment necessary. 
Disabled, must be force fed and helped to perform 
ADL (letargy grade 4). Remaining most of the time in 
lateral decubitus and stands up only for defecation or 
urination; slight restrainment for examination or 
treatment still necessary. 
10 Moribund, fatal processes 
progressing rapidly. 
Absent ADL, dog remains constantly in lateral 
decubitus, even during defecation or urination; 
restrainment no longer necessary for examination or 
treatment, moribund. 
0 Death. Death. 
 
Non-owned dogs were housed at the facilities of 
the Center of Zoonosis Control. They were fed a 
balanced diet and had free tap water. Animals 
with concomitant purulent inflammatory disease 
received antibiotic therapy. If necessary, 
parenteral fluid therapy or nutrition was applied. 
After therapy of accompanying diseases, the 
animals were treated with vincristine sulphate 
(0.025mg/kg) (Das and Das, 2000; Nak et al., 
2005) administered in the cephalic vein at 
weekly intervals until the tumor had 
macroscopically disappeared, which was defined 
as complete remission. 
 
During chemotherapy, all animals were 
submitted to a complete clinical examination at 
weekly intervals. Basic clinical data were 
recorded, such as weight, CKS and SKS, and the 
occurrence of adverse events, which were 
described and graded according to suggestions of 
the Veterinary Co-operative Oncology Group 
(VCOG 2004). When necessary, treatment 
support was given as aforementioned. 
 
In order to measure the reproducibility of the 
newly developed CKS, two veterinarians (MLV 
and KSC) rated independently 32 randomly 
selected dogs, which did not enter the main 
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study. The inter-observer reproducibility was 
measured with the help of the kappa statistics – 
Graphpad software/2008. CKS values at the 
beginning and at the end of therapy were 
compared with the help of the Wilcoxon test and 
frequencies with the chi-square or McNemar test. 
Time-event curves were analyzed with the log-
rank test and the Cox proportional hazards 
regression model. For the survival study, the 
period of observation was from the beginning of 
chemotherapy to the fourth week after complete 
remission. Animals were censored, when therapy 
was abandoned or when they died due to an 
accident. For the evaluation of the adverse 
events, the time from the beginning to the end of 
chemotherapy was recorded.  
 
The first adverse event observed during therapy 
was defined as “event”. Initially, the covariates: 
gender, breed, weight, status as owned dog, 
tumor volume, logarithmated tumor volume, the 
season of the year, SKS, CKS, and the presence 
of concomitant purulent inflammation or 
cachexia were tested individually in univariate 
analyses. Then, those variables with P<0.10 
entered a multivariate Cox regression (stepwise 
backward conditional with P=0.05 for input and 
P=0.10 for output). The proportionality 
assumption was always checked. Furthermore, 
the R
2
 values of the regressions were calculated 
(Lorand-Metze et al., 2004; Rybka et al., 2008), 
which represent the goodness-of-fit of the 
mathematical model; thus, estimating the 
approximation of the algorithm to clinical and 
biological reality. Then, for both multivariate 
Cox models, 100 new data sets were created, 
each by bootstrap resampling of the original data 
with replacement. In an individual new bootstrap 
sample, a patient may be represented once, 
multiple times, or not at all. The Cox-regression 
was applied to every new data set and the 
independent variables were recorded. This 
procedure is very useful to test the stability of the 
initially obtained mathematical model and points 
out the most important independent variables 
(Lorand-Metze et al., 2004). Finally, a cluster 
analysis according to the Ward algorithm (Metze 
et al., 2000; Oliveira et al., 2001) was applied on 
the CKS values. Survival differences of the 
groups were analyzed with the log-rank test. For 
statistical tests, Winstat 3.1 and SPSS 10.0 
software were used. 
 
RESULTS 
 
In 71 animals, the tumor was located at the vulva 
or vagina; in 13, at the penis; in one case, at the 
lower lip; and in another dog, at the lower eyelid. 
Fifty-two dogs were owned, 83 of mixed breed. 
Tumor size ranged from 0.7cm
3
 to 121.5cm
3
 
(median 11.45cm
3
). Eleven animals suffered 
from seborrheic dermatitis, 19 from alopecia, and 
five revealed areas of erythema. In 19 animals, a 
purulent inflammatory process was diagnosed, 
e.g. ulcerated tumor, purulent anal secretion, 
otitis etc. Four animals showed slight to 
moderate weight loss. Three animals revealed 
skin tumors unrelated to CTVT and two dogs had 
sequelae from previous fractures. One dog 
suffered from dehydration. Ten dogs showed 
mild and seven moderate lethargy. When 
comparing the frequency of animals with 
concomitant purulent inflammatory diseases 
admitted in hot or cold months, there were no 
significant differences (Table 2). 
 
Table 2. Changes of the modified Karnofksy score in subgroups comparing values at the beginning and at 
the end of treatment (Wilcoxon test) of dogs 
CKS/ 
Concomitant 
disease 
 
Cold 
and 
dry 
months 
(n=27) 
Hot 
and 
rainy 
months 
(n=66) 
Owned 
(n=53) 
Non-
owned 
(n=40) 
Male 
(n=15) 
Female 
(n= 
78) 
Mongrel  
(n=83) 
Breed 
(n=10) 
Purulent 
inflammation 
(n=20) 
Without 
purulent 
inflammation 
(n=73) 
CKS at the 
beginning 
 
 
88.5 
 
84.7 
 
87.0 
 
84.3 
 
85.6 
 
87.1 
 
85.5 
 
88.0 
 
77.0 
 
88.2 
 
CKS at 
the end  
 
P value 
 
94.8 
 
 
0.01 
 
85.8 
 
 
0.05  
 
92.6 
 
 
0.0001 
 
82.8 
 
 
0.78 
 
87.3 
 
 
0.027  
 
94.3 
 
 
0.011 
 
88.8 
 
 
0.004 
 
85.0 
 
 
0.50 
 
84.0 
 
 
0.039 
 
89.6 
 
 
0.049 
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In the pilot study, the interobserver 
reproducibility of the CKS had high concordance 
(kappa=0.735; weighted kappa=0.835). At 
admission, 23 dogs with CTVT had a CKS of 
100, 33 of 90, and 20 of 80. Ten animals of 70, 
six of 60, and one dog had 50. The mean CKS 
value (considering all animals) improved from 
85.8 to 88.4. In nine dogs, a temporary decrease 
of the CKS values was seen, predominantly in 
the second or third weeks, but then they returned 
to pre-treatment levels. When treatment was 
done during the „cold and dry period‟, CKS 
increased more during treatment than in „hot and 
rainy months‟. Mongrel dogs or owned dogs 
showed a significant improvement of the CKS 
values, whereas this was not the case for non-
owned animals or dogs with breed (Table 2). 
 
Complete remission was achieved in 75 dogs 
with a median of five injections (ranging from 1 
to 16). The remaining 18 animals had abandoned 
therapy and seven expired.  
 
The median observation time for the study on 
adverse events was four weeks (ranging from 1 
to 14 weeks). During chemotherapy, 17 animals 
presented one to five adverse events which were 
observed from the second to the 10
th
 week. Four 
animals presented a temporary weight of loss 
(grade 2) but regained weight at the end of 
treatment. Their CKS did not significantly 
change from the beginning to the end of the 
therapy. Five animals suffered a progressive 
permanent weight of loss (grades 2 and 3, two 
animals each), which was paralleled by a 
significant decrease of the CKS values (mean: 
50; P=0.04). Ten dogs developed serous nasal 
secretion, whereas this had not been observed in 
any dog before treatment (P<0.01). When each 
variable was tested for the occurrence of adverse 
events, the Cox regression revealed neither CKS 
(P=0.19) nor SKS (P=0.30) as favorable factors. 
When treatment was started in the „hot and rainy 
months‟, there was an increased probability to 
develop adverse events (P=0.029, Cox Mantel–
test) (Figure 1). Whereas only one of 27 dogs 
showed an adverse event during the „cold and 
dry months‟, 23 of 66 animals revealed at least 
one adverse event in the „hot and rainy period‟. 
In the univariate Cox regressions, all clinical 
variables, including the SKS, did not enter the 
univariate Cox models.  
 
 
Figure 1. Seasonal variation of the occurrence of 
adverse events in dogs. June – August 
corresponding to cold and dry months; 
September – May corresponding to hot and rainy 
months (P=0.029; Cox Mantel–test). 
 
A total of seven animals died during therapy, two 
of them suffered a sudden unexpected death 
without presenting adverse events or a previous 
decline in CKS. Two animals expired due to 
causes not related to pre-existing diseases or 
therapy, i.e. a car accident and a snake bite, and 
were therefore considered censored cases. At the 
time of death, only the dog expiring due to a 
snake bite had achieved complete remission. The 
median observation time of the survival study 
was nine weeks (ranging from 1 to 21). When 
analyzing survival in univariate analyses, weight 
(B=-0.298; P=0.017), CKS (B=- 0.0962; 
P=0.0015), SKS (B=1.35; P=0.054), but not the 
status as owned dog (P=0.58) were favorable, 
whereas underweight (P=0.57) or purulent 
inflammation at diagnosis (P=0.63), gender 
(P=0.42), breed (P=0.88), tumor volume 
(P=0.74), and “season”(P=0.53), did not reveal 
prognostic importance regarding survival. In the 
multivariate model, only the variables CKS (B=-
0.0766; P=0.0213) and weight (B=-0.2386; 
P=0.0368) showed to be independent prognostic 
parameters for survival during therapy. In 100 
bootstrap resampling models, the variable CKS 
entered in 93% and weight in 91% of the models, 
whereas the variable SKS appeared only in 2% 
of the bootstrap models. When applying a cluster 
analysis to the CKS values before therapy, two 
groups were created by the Ward algorithm: dogs 
with CKS=100 and those with CKS<100. 
Whereas all 24 animals with a modified 
Karnofsky score of 100 admission had survived, 
seven of the 69 animals with CKS from 50 and 
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90 to expired (Figure 2). Both groups showed a 
statistically significant difference in the log-rank 
test (P=0.011). 
 
 
Figure 2. Overall survival during the treatment of 
canine transmissible venereal tumor according to 
the modified Karnofsky score at diagnosis.  
CKS corresponding to modified Karnofsky 
performance score adapted for dogs (P=0.011; 
Cox Mantel-test). 
 
DISCUSSION 
 
Vincristine is a frequently prescribed agent in 
veterinary medicine due to its widespread use for 
feline and canine malignant lymphomas. The 
gastrointestinal and neurological symptoms, 
weight loss, and anemia, which were observed in 
the present study during chemotherapy, are well 
known complications of this therapy (Nak et al., 
2005). Cough and dyspnea may also be caused 
by therapy, since acute and chronic pulmonary 
dysfunction has also been reported (Hahn et al., 
1994). Increased nasal secretion, however, as 
observed in this investigation, has to the 
knowledge of the authors not been reported 
during vincristine therapy. It could be speculated 
that this phenomenon might be due to an 
increased susceptibility to viral infections in the 
upper respiratory tract during treatment. But a 
causal relationship cannot be postulated at the 
moment, since this study did not include a 
treatment-free control-group due to ethical 
reasons. An important factor for the occurrence 
of adverse events in this prospective 
investigation was the season, which has shown to 
be important in human (Metze et al., 1994; 
Lorand-Metze et al., 1998), as well in veterinary 
medicine (Brown-Brandl et al., 2005; Lacetera et 
al., 2005). Recently, it had been demonstrated 
that during hot and rainy months CTVT 
remission was delayed (Scarpelli et al., 2010), 
which might be due to a seasonal modulation of 
the immune system. High environmental 
temperature may influence the immune system 
(Brown-Brandl et al., 2005; Lacetera et al., 2005) 
and increase the frequency of infectious diseases 
in cattle (Brown-Brandl et al., 2005). Similar 
mechanisms might be responsible for the higher 
number of complications during vincristine 
therapy in hot months as documented in this 
study. An alternative explanation, however, 
would be a seasonal increase in diseases not 
related to chemotherapy. In order to investigate 
this possibility, the frequency of concomitant 
inflammatory diseases, underweight, and the 
CKS values before starting chemotherapy were 
compared from hot to cold months, but 
significant differences were not found. It could 
be hypothesized, that the combination of 
vincristine chemotherapy together with hot 
environmental temperatures might be responsible 
for the increased frequency of adverse events, 
perhaps due to a modulation of the immune 
system. But, additional investigations are 
necessary to clarify this question.  
 
Ogilvie et al. (1989) evaluated the toxic effects 
of doxorubicine in dogs with a modified 
Karnofsky performance score and related a 
significant decrease of the score values provoked 
by doxorubicin-induced toxicosis. In this study, 
however, it is difficult to evaluate, whether 
unfavourable clinical signs or diseases occurring 
during therapy are related to vincristine or the 
pre-existing diseases. Therefore, it was used the 
term „adverse event‟, which, in the context of 
chemotherapy, may or may not be considered 
related to the medical treatment (VCOG 2004). 
Hahn et al. (1994) applied the SKS in dogs with 
malignant lymphomas, but they were not able to 
demonstrate any prognostic relevance regarding 
remission or survival time.  
 
In the present study, this simplified score 
composed of only five categories was compared 
to a more detailed performance score which was 
based on the Karnofsky performance score for 
humans (Karnofsky and Burchenal, 1949), 
comprising 11 categories. Due to mathematical 
reasons, a measurement system achieves a higher 
test power when it is based on a more detailed 
scoring system, i.e. it will detect more easily 
even small differences as significant. This 
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phenomenon explains the better performance of 
the CKS.  
 
Death has been reported during vincristine 
therapy of CTVT ( Nak et al., 2005). Therefore, 
one aim of this study was to find out whether the 
CKS could predict animals with a higher risk for 
death during chemotherapy. Regarding survival, 
both scores demonstrated to be of prognostic 
value in univariate Cox regressions, but in the 
multivariate Cox model, only the CKS entered 
the final model. The difference was also evident 
in the bootstrap resampling study. Whereas CKS 
was present in 93% of all models, the simplified 
Karnofsky score was only in 2%. The R
2
 values 
also showed a striking difference. The variance 
of CKS explains 10.8% of the variance of the 
Cox regression, compared with only 3.1% of the 
simplified score. The main argument for the 
application of a more simplified score system is 
its reproducibility, because a diminished number 
of categories usually increases the concordance 
rate between different observers. In this case the 
interobserver reproducibility, as measured by the 
kappa values, it was excellent for the CKS, thus 
underlining its clinical utility in veterinary 
medicine.  
 
In summary, the Karnofsky score adapted for 
dogs, presented in this investigation, is a simple, 
cheap, and reproducible clinical instrument, able 
to estimate the outcome of the patient during 
treatment of CTVT. 
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